Marksans Pharma
MARKSANS · Pharma > Pharmaceuticals & Drugs · Chairman: Mark Saldanha · MD: Mark Saldanha · Listing date: Jan. 22, 2002 · Employees: 1138 · Mumbai · http://www.marksanspharma.com

Stock Price vs Company Growth
1d
1.7%
1w
16.9%
1m
22.1%
3m
50.2%
6m
79.6%
1y
77.1%
5y
36.1%
10y
23.3%
all
19.2%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 326 1.7%
210
346
Company Overview

Sales
3,172 Cr
Growth: 15.1%
Profit after Tax
517 Cr
Growth: 23.7%
Mid Cap
14,778 Cr
P/E: 28.6x
Industry P/E: 31.7x
Fundamentals

Sales (Cr) ₹ 3,172
Growth 15.1%
EBITDA 22.5%
P/S 4.7x
Dividend 0.4%
P/E 28.6x
Book Value ₹ 70.2
PEG Ratio 1.9x
ROE 17.9%
P/B 4.7x
Shareholding Pattern

Institutions
Promoters
Mark Saldanha
48.25 %
Others
Mukul Mahavir Prasad Agrawal
1.47 %
Increase    Decrease    No change
Company Profile Detailed

The company is a globally-trusted, customer-centric pharmaceutical company with a strong presence in regulated markets. The company specialises in developing and manufacturing & distributing both over-the-counter (OTC) and prescription (Rx) drugs, aligning its offerings with the evolving needs of patients and healthcare providers across the world.
Investors (49)
Followers (8)